GERN

GERON CORP

8 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bearishMay 27

Increase of 4.5 million shares in the equity incentive pool creates potential for shareholder dilution.

dilution risk

60%

neutralMay 27

Re-election of Class III directors ensures leadership continuity.

management change

40%

bullishMay 27

Expanded equity plan allows for non-cash compensation to attract top talent.

capital raise

50%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

bullishMay 6

Net product revenue grew 31% YoY to $51.8 million.

earnings beat

70%

bearishMay 6

Gross-to-net adjustments increased from 13% to 20.8% of gross sales.

margin compression

60%

bullishMay 6

Operating expenses decreased 8% due to workforce reduction.

margin expansion

50%

neutralMay 6

Facing multiple securities class action and derivative lawsuits regarding RYTELO potential.

regulatory action

40%

Filing History

8-KMay 27, 2026

Geron's 8-K filing reveals a company at a governance crossroads, balancing the need for aggressive talent acquisition against the risk of shareholder dilution. The approval of the Amended 2018 Plan provides the company with the necessary tools to incentivize a world-class team, but the voting patterns indicate a fragmented investor base. The overall impact is a cleared path for management to execute its growth strategy, though the market will likely remain sensitive to how these new shares are deployed and whether the company can achieve commercial milestones before further capital raises are required.

10-QMay 6, 2026

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and structural financial instability. On one hand, the growth in RYTELO sales and the ability to reach a near-breakeven operating point suggest that the commercial engine is functioning. On the other hand, the rising cost of sales and the persistence of net losses highlight the difficulty of transitioning to a self-sustaining business model. Investors are now weighing the potential of the European expansion and the IMpactMF trial results against the risks of debt covenants and litigation settlements. The critical metric moving forward will be whether Geron can stabilize its gross-to-net adjustments and maintain revenue growth without further equity dilution or reliance on additional debt tranches.